Publications by authors named "F D McKeon"
Since its discovery over 35 years ago, MDM2 has emerged as an attractive target for the development of cancer therapy. MDM2's activities extend from carcinogenesis to immunity to the response to various cancer therapies. Since the report of the first MDM2 inhibitor more than 30 years ago, various approaches to inhibit MDM2 have been attempted, with hundreds of small-molecule inhibitors evaluated in preclinical studies and numerous molecules tested in clinical trials.
View Article and Find Full Text PDFArticle Synopsis
- CFTR modulator drugs improve lung function and body mass index in cystic fibrosis patients, but inflammation remains a challenge, indicating a need to target the underlying causes in the lungs of patients with established disease.* -
- The study explores the presence of unique, potentially pathogenic stem cell variants in cystic fibrosis lungs, similar to those found in COPD, and aims to identify which of these variants contribute to ongoing inflammation.* -
- Research utilized advanced stem cell cloning technology on end-stage CF lungs to identify five predominant stem cell variants, three of which are pro-inflammatory, highlighting the complexity of stem cell involvement in cystic fibrosis lung inflammation.*
Article Synopsis
- Idiopathic pulmonary fibrosis (IPF) is a severe lung disease characterized by the replacement of healthy lung tissue with dense fibrotic tissue, leading to progressive respiratory failure.
- Research utilizing single-cell RNA sequencing has uncovered a specific type of stem cell in IPF patients that is capable of converting normal lung cells into harmful myofibroblasts, suggesting a critical role in disease progression.
- Drug testing revealed that this profibrotic stem cell variant may be targeted with specific inhibitors, indicating potential new therapeutic approaches for treating IPF.